Sector ratings Monte Rosa Therapeutics, Inc.

Stocks

Market Closed - Nasdaq Other stock markets 16:00:00 2026-08-11 EDT			5-day change	1st Jan Change
15.76 ^USD	-0.38%		-1.99%	+0.51%

08-06	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-06	Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q2 Collaboration Revenue $9.0M, vs. FactSet Est of $12.9M	MT

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Global Valuation
MONTE ROSA THERAPEUTICS, INC.	1.34B	-	BB	-	-
LONZA GROUP AG	49.54B		AAA
REVOLUTION MEDICINES, INC.	44.06B	-	B	-	-
BEONE MEDICINES AG	40.85B		-
IQVIA HOLDINGS INC.	40.14B		AAA
CELLTRION, INC.	34.17B		A
ASCENDIS PHARMA A/S	16.78B	-	-	-	-
MEDPACE HOLDINGS, INC.	16.9B		BBB
EUROFINS SCIENTIFIC SE	14B		AA
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	13.46B		AA
ICON PUBLIC LIMITED COMPANY	12.78B		AAA
PHARMARON BEIJING CO., LTD.	11.75B		AA
BIO-TECHNE CORPORATION	11.24B		AA
ABIVAX	10.94B	-	BBB	-	-
PRAXIS PRECISION MEDICINES, INC.	10.35B	-	B	-	-
APOGEE THERAPEUTICS, INC.	10.11B	-	B	-	-
TEMPUS AI, INC.	10.05B		A		-
PROTAGONIST THERAPEUTICS, INC.	9.6B		BB		-
IONIS PHARMACEUTICALS, INC.	9.21B	-	A	-	-
QIAGEN N.V.	8.82B		AAA
Average	18.8B		A
Weighted average by Cap.			A